[27] [28] [32] Exenatide was predicted by Amylin scientist Alain Baron to begin undergoing the Food and Drug Administration's approval process in 2004
Hanens More Than Words programme equips parents with the skills to support their childs communication development at home
The trial also showed improvements in: Blood pressure Triglycerides Inflammatory markers Meanwhile, the SURMOUNT-2 trial , which studied patients with type 2 diabetes, demonstrated similar benefits, proving GLP-1s are effective even in populations with metabolic challenges
Results showed that puerarin restored the disturbed intestinal microecology by enriching amino acid metabolism, butyric acid generation, and LPS biosynthesis, herein alleviating osteoporosis
[DOI] [PubMed] [Google Scholar] 59.Douglas LA, Varlinskaya EI, Spear LP